[Bronchopulmonary dysplasia and corticosteroid therapy]

Area of Science:

• Neonatal medicine
• Pediatric pulmonology
• Pharmacology

Background:

• Inflammation is key in bronchopulmonary dysplasia (BPD) development in preterm infants.
• Corticosteroids possess anti-inflammatory properties, making them a potential treatment for BPD.
• Antenatal steroid exposure offers protection against BPD development.

Purpose of the Study:

• To evaluate the efficacy and safety of antenatal and postnatal corticosteroid use in managing bronchopulmonary dysplasia.
• To compare the effects of early systemic dexamethasone versus inhaled steroids on BPD outcomes.

Main Methods:

• Review of studies on antenatal and postnatal corticosteroid administration for BPD.
• Analysis of outcomes including mechanical ventilation duration, oxygen therapy, and BPD incidence/severity.
• Comparison of adverse effects associated with different corticosteroid administration routes and timing.

Main Results:

• Postnatal systemic steroids shorten mechanical ventilation and oxygen therapy duration but carry short- and long-term risks.
• Early postnatal dexamethasone (within 7 days of life) decreases BPD incidence and severity at 28 days and 36 weeks post-conceptional age.
• Inhaled steroids show fewer adverse effects than systemic dexamethasone but are less effective in treating BPD.

Conclusions:

• Corticosteroids, particularly early postnatal dexamethasone, are effective in managing BPD in preterm infants.
• The choice between systemic and inhaled steroids involves balancing efficacy against adverse effects.
• Further research into optimal steroid regimens is warranted to improve BPD outcomes while minimizing harm.